TPIV 100

Drug Profile

TPIV 100

Alternative Names: TPIV-100

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator TapImmune
  • Developer Mayo Clinic; TapImmune
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 07 Jun 2016 Mayo Clinic files an IND application with the US FDA in USA for Breast Cancer before June 2016
  • 07 Jun 2016 TapImmune exercises its option agreement and in-licenses worldwide rights to HER2neu vaccine technology from Mayo Clinic
  • 07 Dec 2015 Efficacy data from a phase I trial in Breast cancer released by TapImmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top